Scientists examined the effects of a rapamycin pretreatment of epithelial cell adhesion molecule (EpCAM) chimeric antigen receptor (CAR)-T cells and assessed the in vivo antitumor efficacy of rapamycin pretreated EpCAM CAR-T cells and CD33 CAR-T cells in leukemia xenograft mouse models.
[Clinical Cancer Research]